ArticleClinical case reports2025
Autologous Fibroblast Cells in Platelet-Rich Plasma Injection as a Novel Treatment for Inactive En Coup de Sabre Deformity.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autologous Fibroblast Cells in Platelet-Rich Plasma Injection as a Novel Treatment for Inactive En Coup de Sabre Deformity.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphea is a chronic autoimmune condition characterized by sclerosis and scar-like changes in the skin and underlying tissues. En coup de sabre represents a rare and severe linear variant of morphea, primarily affecting the frontoparietal scalp and forehead, with a higher prevalence among children and women. The disease often leads to significant cosmetic and functional impairments, posing therapeutic challenges due to its unpredictable course and varying responses to conventional treatments. Current management strategies include topical steroids, calcineurin inhibitors, systemic therapies, such as methotrexate, and ultraviolet (UV) therapy. Additionally, interventions like fat grafting and hyaluronic acid injections have demonstrated some efficacy in restoring tissue volume and improving skin texture. This case report explores an innovative approach using autologous fibroblast cell injection combined with platelet-rich plasma (PRP) as a novel therapeutic option for a 40-year-old woman diagnosed with inactive-phase en coup de sabre. After harvesting fibroblast cells from a superficial skin biopsy and isolating PRP through centrifugation, the combined solution was administered via three monthly subcutaneous injections. No adverse effects were observed throughout the treatment period. At a 3-month follow-up, significant improvements were noted in skin elasticity, hydration, and overall cosmetic appearance. Ultrasound imaging revealed enhanced dermal thickness and density, while cutometric and colorimetric assessments confirmed increased skin viscoelastic properties and brightness. The promising results observed in this case suggest that the combination of autologous fibroblasts and PRP may offer a safe, effective, and minimally invasive therapeutic alternative for managing en coup de sabre morphea. However, larger studies and controlled clinical trials are essential to validate these findings, optimize treatment protocols, and further understand the underlying mechanisms driving tissue regeneration and repair in morphea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.